Achillion To Present At The Wells Fargo 2013 Healthcare Conference

NEW HAVEN, Conn., June 12, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, President and Chief Executive Officer of Achillion, and members of the senior management team will present a corporate update and participate on a HCV Panel at the Wells Fargo 2013 Healthcare Conference on Tuesday, June 18, 2013 at 8:50 a.m. and 10:00 a.m. EDT, respectively, at the Intercontinental Hotel in Boston, MA.

The live audio broadcasts and the subsequent archived webcasts of the Company's presentations will be available on the Company's website, http://www.achillion.com, under the "News Center" section. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's discovery, clinical development, and commercial teams have advanced multiple novel product candidates with proven mechanisms of action into studies and toward the market. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.
CONTACT: Company Contact:         Glenn Schulman         Achillion Pharmaceuticals, Inc.         Tel. (203) 752-5510         gschulman@achillion.com                  Investors:         Mary Kay Fenton         Achillion Pharmaceuticals, Inc.         Tel. (203) 624-7000         mfenton@achillion.com

Achillion Pharmaceuticals logo

If you liked this article you might like

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence